Acceleron Pharma (XLRN) Tops Q2 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. AXP
9. ZETA
10. DAL

Go back to Acceleron Pharma (XLRN) Tops Q2 EPS by 1c

Acceleron Reports Second Quarter 2018 Operating and Financial Results

August 2, 2018 4:06 PM EDT

MEDALIST and BELIEVE Phase 3 trials met all primary and key secondary endpoints

ACE-083 Part 2 of the Phase 2 trials in facioscapulohumeral muscular dystrophy and Charcot-Marie-Tooth disease are underway

PULSAR Phase 2 trial initiated with sotatercept in pulmonary arterial hypertension

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2018.

... More